Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 20/3012% below fair value
$167.40−2.00 (-1.18%)
Close on Nov 13, 2026Market cap $17.02BP/E 24.8Yield –
Neurocrine Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Neurocrine Biosciences's operating margin for the twelve months ending Sep 30, 2026 was 24.0%. For fiscal 2025 it was 21.6%, against 24.2% the year before. The highest annual figure on record is 43.8% in fiscal 2011.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.6% | −2.6 |
| FY2024 | Dec 31, 2024 | 24.2% | +10.9 |
| FY2023 | Dec 31, 2023 | 13.3% | −3.4 |
| FY2022 | Dec 31, 2022 | 16.7% | +7.7 |
| FY2021 | Dec 31, 2021 | 9.0% | −6.5 |
| FY2020 | Dec 31, 2020 | 15.6% | +6.4 |
| FY2019 | Dec 31, 2019 | 9.2% | +1.0 |
| FY2018 | Dec 31, 2018 | 8.2% | +89.4 |
| FY2017 | Dec 31, 2017 | -81.3% | +901.2 |
| FY2016 | Dec 31, 2016 | -982.5% | −506.0 |
| FY2015 | Dec 31, 2015 | -476.5% | +1225.4 |
| FY2013 | Dec 31, 2013 | -1701.9% | −1704.6 |
| FY2012 | Dec 31, 2012 | 2.7% | −41.1 |
| FY2011 | Dec 31, 2011 | 43.8% | +84.8 |
| FY2010 | Dec 31, 2010 | -41.0% | +1776.5 |
| FY2009 | Dec 31, 2009 | -1817.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 29.5% | −0.6 |
| Q2 FY2026 | Jun 30, 2026 | 15.8% | −5.4 |
| Q1 FY2026 | Mar 31, 2026 | 23.7% | +19.6 |
| Q4 FY2025 | Dec 31, 2025 | 26.2% | +3.6 |
| Q3 FY2025 | Sep 30, 2025 | 30.1% | +0.5 |
| Q2 FY2025 | Jun 30, 2025 | 21.2% | −3.5 |
| Q1 FY2025 | Mar 31, 2025 | 4.1% | −15.1 |
| Q4 FY2024 | Dec 31, 2024 | 22.6% | −6.6 |
| Q3 FY2024 | Sep 30, 2024 | 29.5% | +1.2 |
| Q2 FY2024 | Jun 30, 2024 | 24.6% | +8.4 |
| Q1 FY2024 | Mar 31, 2024 | 19.3% | +46.4 |
| Q4 FY2023 | Dec 31, 2023 | 29.2% | +4.1 |
| Q3 FY2023 | Sep 30, 2023 | 28.3% | +5.7 |
| Q2 FY2023 | Jun 30, 2023 | 16.3% | +1.8 |
| Q1 FY2023 | Mar 31, 2023 | -27.2% | −28.2 |
| Q4 FY2022 | Dec 31, 2022 | 25.1% | +36.7 |
| Q3 FY2022 | Sep 30, 2022 | 22.6% | +7.6 |
| Q2 FY2022 | Jun 30, 2022 | 14.5% | −7.3 |
| Q1 FY2022 | Mar 31, 2022 | 1.0% | −12.3 |
| Q4 FY2021 | Dec 31, 2021 | -11.6% | −40.6 |
| Q3 FY2021 | Sep 30, 2021 | 15.0% | +32.2 |
| Q2 FY2021 | Jun 30, 2021 | 21.7% | −3.6 |
| Q1 FY2021 | Mar 31, 2021 | 13.3% | −11.5 |
| Q4 FY2020 | Dec 31, 2020 | 29.0% | +9.0 |
| Q3 FY2020 | Sep 30, 2020 | -17.1% | −57.7 |
| Q2 FY2020 | Jun 30, 2020 | 25.3% | +6.6 |
| Q1 FY2020 | Mar 31, 2020 | 24.8% | +97.8 |
| Q4 FY2019 | Dec 31, 2019 | 20.0% | +3.4 |
| Q3 FY2019 | Sep 30, 2019 | 40.6% | +4.8 |
| Q2 FY2019 | Jun 30, 2019 | 18.7% | +20.7 |
| Q1 FY2019 | Mar 31, 2019 | -73.0% | −20.3 |
| Q4 FY2018 | Dec 31, 2018 | 16.6% | +4.0 |
| Q3 FY2018 | Sep 30, 2018 | 35.8% | +45.7 |
| Q2 FY2018 | Jun 30, 2018 | -1.9% | +902.1 |
| Q1 FY2018 | Mar 31, 2018 | -52.7% | – |
| Q4 FY2017 | Dec 31, 2017 | 12.5% | – |
| Q3 FY2017 | Sep 30, 2017 | -9.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -904.0% | – |
See a number that looks wrong?